Tag: HBcAb
-
Low HBV Reactivation Risk After Tenofovir Withdrawal in People with HIV: New EACS 2025 Findings
Background: Tenofovir and HBV in HIV Care Tenofovir has been a cornerstone of antiretroviral therapy (ART) for people living with HIV, partly because it also provides activity against hepatitis B virus (HBV). For patients with past HBV exposure who are virologically suppressed, clinicians have explored strategies to reduce long-term drug toxicity—especially renal and bone side…
-
Low Risk of HBV Reactivation After Tenofovir Withdrawal in People With HIV
New evidence supports safety of tenofovir-sparing ART in HBV-immune people with HIV Emerging data presented at the 2025 European AIDS Clinical Society (EACS) Congress suggest that stopping tenofovir in people with HIV who have prior hepatitis B exposure poses a very small risk of hepatitis B virus (HBV) reactivation. The findings come from the Swiss…